peoplePerson
Alexander Eggermont
Surgical oncologist who led the EORTC adjuvant ipilimumab and pembrolizumab trials in melanoma.
Alexander Eggermont led EORTC 18071 (adjuvant ipilimumab) and KEYNOTE-054 (adjuvant pembrolizumab) in stage III melanoma, and served as EORTC President and Director General of Gustave Roussy.
| Title | Journal | Year |
|---|---|---|
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (KEYNOTE-054) | NEJM | 2018 |
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-006
Shares Ipilimumab, Pembrolizumab, Melanoma.
- PersonUlrich Keilholz
- IdeaPredict immune side-effects before they happen and pre-empt them
Shares Ipilimumab, Pembrolizumab.
- PersonAurélien Marabelle
Shares Gustave Roussy, Pembrolizumab.
- TrialKEYNOTE-716
Shares Pembrolizumab, Melanoma.
- PairingPD-1 failure → TIL therapy
Shares Pembrolizumab, Melanoma.
- PersonIgor Puzanov
Shares Ipilimumab, Melanoma.
- PairingNeoadjuvant immunotherapy → response-adapted adjuvant
Shares Ipilimumab, Pembrolizumab, Melanoma.